

# Optic Nerve Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/O9E5747524BDEN.html>

Date: May 2024

Pages: 132

Price: US\$ 6,499.00 (Single User License)

ID: O9E5747524BDEN

## Abstracts

The 7 major optic nerve diseases markets are expected to exhibit a CAGR of 3.46% during 2024-2034.

The optic nerve diseases market has been comprehensively analyzed in IMARC's new report titled "Optic Nerve Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Optic nerve diseases refer to a group of medical conditions that affect the optic nerve, which is a crucial structure responsible for transmitting visual information from the eyes to the brain. The symptoms and severity of the ailments can vary based on the extent of nerve damage and its underlying cause. Some common indications include blurry vision, loss of peripheral vision, changes in color vision, pain in the eyes, decreased contrast sensitivity, photophobia, impaired pupillary reflexes, uncontrolled, rhythmic eye movements, etc. In rare cases, these illnesses can lead to hallucinations that may be simple patterns, shapes, or more complex visual scenes. The diagnosis of optic nerve diseases typically involves a combination of clinical evaluation, medical history assessment, and eye tests. A funduscopy, which uses an ophthalmoscope, is also recommended to examine the back of the eye and check for any signs of damage or swelling. The healthcare provider may further perform the optical coherence tomography (OCT) technique that provides cross-sectional pictures of the retina to measure the thickness of the nerve fiber layer and confirm the underlying cause in patients.

The escalating cases of glaucoma, which can compress and damage the delicate fibers of the optic nerve due to increased intraocular pressure, are primarily driving the optic nerve diseases market. In addition to this, the rising incidences of various associated risk factors, including infections, usage of certain medications, structural abnormalities,

head injuries, eye trauma, advancing age, etc., are creating a positive outlook for the market. Moreover, the widespread adoption of intravenous immunoglobulin (IVIG) therapy, since it can potentially help to preserve optic nerve function and slow down the progression of damage, is further bolstering the market growth. Apart from this, the inflating application of plasmapheresis techniques, which can remove harmful substances, like antibodies or toxins, from the bloodstream, thereby enhancing the treatment outcomes in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of laser therapy to improve the drainage of fluid from the eyes, repair damaged nerve fibers, and reduce intraocular pressure is expected to drive the optic nerve diseases market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the optic nerve diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for optic nerve diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the optic nerve diseases market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

## Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the optic nerve diseases market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the optic nerve diseases market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current optic nerve diseases marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the optic nerve diseases market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the optic nerve diseases market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the optic nerve diseases market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of optic nerve diseases across the seven major markets?

What is the number of prevalent cases (2018-2034) of optic nerve diseases by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of optic nerve diseases by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with optic nerve diseases across the seven major markets?

What is the size of the optic nerve diseases patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of optic nerve diseases?

What will be the growth rate of patients across the seven major markets?

### Optic Nerve Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for optic nerve diseases drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the optic nerve diseases market?

What are the key regulatory events related to the optic nerve diseases market?

What is the structure of clinical trial landscape by status related to the optic nerve diseases market?

What is the structure of clinical trial landscape by phase related to the optic nerve diseases market?

What is the structure of clinical trial landscape by route of administration related to the optic nerve diseases market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 OPTIC NERVE DISEASES - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 OPTIC NERVE DISEASES - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 OPTIC NERVE DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 OPTIC NERVE DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 OPTIC NERVE DISEASES - UNMET NEEDS**

## **10 OPTIC NERVE DISEASES - KEY ENDPOINTS OF TREATMENT**

## **11 OPTIC NERVE DISEASES - MARKETED PRODUCTS**

- 11.1 List of Optic Nerve Diseases Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Rocklatan (Latanoprost/netarsudil) - Alcon
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Durysta (Bimatoprost sustained-release) - AbbVie
    - 11.1.2.1 Drug Overview



- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Lumigan (Bimatoprost) - AbbVie
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Uplizna (Inebilizumab) - Horizon Therapeutics plc
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Enspryng (Satralizumab) - Chugai Pharmaceuticals/Roche
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 OPTIC NERVE DISEASES - PIPELINE DRUGS**

- 12.1 List of Optic Nerve Diseases Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 NCX 470 - NicOx
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy
    - 12.1.1.5 Regulatory Status
  - 12.1.2 STN1012600 - Santen Pharmaceutical
    - 12.1.2.1 Drug Overview
    - 12.1.2.2 Mechanism of Action
    - 12.1.2.3 Clinical Trial Results
    - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 QLS-101 - Qlaris Bio
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 Ravulizumab - Alexion AstraZeneca Rare Disease
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. OPTIC NERVE DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. OPTIC NERVE DISEASES – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 OPTIC NERVE DISEASES - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Optic Nerve Diseases - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Optic Nerve Diseases - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Optic Nerve Diseases - Market Size
    - 15.3.1.1 Market Size (2018-2023)

- 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Optic Nerve Diseases - Market Size by Therapies
  - 15.3.2.1 Market Size by Therapies (2018-2023)
  - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Optic Nerve Diseases - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Optic Nerve Diseases - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Optic Nerve Diseases - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Optic Nerve Diseases - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Optic Nerve Diseases - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Optic Nerve Diseases - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Optic Nerve Diseases - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Optic Nerve Diseases - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Optic Nerve Diseases - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Optic Nerve Diseases - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Optic Nerve Diseases - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Optic Nerve Diseases - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Optic Nerve Diseases - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Optic Nerve Diseases - Market Size

- 15.8.1.1 Market Size (2018-2023)
- 15.8.1.2 Market Forecast (2024-2034)
- 15.8.2 Optic Nerve Diseases - Market Size by Therapies
  - 15.8.2.1 Market Size by Therapies (2018-2023)
  - 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Optic Nerve Diseases - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Optic Nerve Diseases - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Optic Nerve Diseases - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Optic Nerve Diseases - Access and Reimbursement Overview

## **16 OPTIC NERVE DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 OPTIC NERVE DISEASES MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 OPTIC NERVE DISEASES MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Optic Nerve Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/O9E5747524BDEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O9E5747524BDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

